Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Staar Surgical

Staar Surgical Stock Earns RS Rating Upgrade

Staar Surgical shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 87.

Investors Business Daily

Staar Surgical Stock Climbs The Leadership Ladder With Jump To 84 RS Rating

A Relative Strength Rating upgrade for Staar Surgical shows improving technical performance.

Investors Business Daily

Staar Surgical, A Lasik Rival, Just Crushed Quarterly Views; But Is Its 2026 Target Too Aggressive?

Staar Surgical preannounced strong first-quarter sales on Thursday, helping Staar stock retake its 200-day line and hit a seven-month high.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

S&P 500 Dividend Standout Leads 5 Resilient Stocks Near Buy Points As Fed Looms

S&P 500 dividend standout Devon Energy leads this weekend's watch list of stocks near buy points in a tough market.

Investors Business Daily

IBD Stock Of The Day Staar Surgical Is Pulling Back — Why You Should Pay Attention

Staar Surgical is the IBD Stock Of The Day. Although STAA stock isn't actionable, shares have weathered a tricky second quarter.

Investors Business Daily

Staar Obliterates Earnings Forecasts Again — And Tacks On Another Sales Beat

Staar Surgical reported better-than-expected second-quarter metrics, leading STAA stock to soar to a nine-month high Thursday.

Investors Business Daily

Here's How Much You Would Have Made Owning Staar Surgical Stock In The Last 20 Years

Staar Surgical (NASDAQ:STAA) has outperformed the market over the past 20 years by 5.45% on an annualized basis producing an average annual return of 12.6%. Currently, Staar Surgical has a market capitalization of $2.88 billion.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Needham Sees Clear View Into STAAR Surgical's Durable Double-Digit Revenue Expansion

Needham is initiating coverage on STAAR Surgical Company (NASDAQ:STAA) with a Buy rating and an $87 price target. The analysts note that FDA approval of STAA's EVO Implantable Collamer Lens (ICLs) should serve as a meaningful tailwind for revenue. The Company generates most of its revenue from outside US markets. But after the FDA approval…

Benzinga

Staar Surgical Rockets After FDA Clears Its Implantable Lens For Nearsightedness

Staar Surgical won Food and Drug Administration clearance for its implantable nearsightedness lens on Monday, leading STAA stock to soar.

Investors Business Daily

Staar Surgical: Q4 Earnings Insights

Staar Surgical (NASDAQ:STAA) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Benzinga

People

Joe Jonas

313 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.